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Introduction
Pyogenic sterile Arthritis Pyoderma gangrenosum and
Acne (PAPA) syndrome is a rare autosomal dominant
inherited autoinflammatory disease caused by mutations
in Proline-serine-threonine phosphatase-interacting pro-
tein 1 (PSTPIP1). In childhood, the syndrome is featured
by recurrent sterile, erosive arthritis, potentially leading
to joint destruction. By puberty, cutaneous symptoms
become predominant, with recurrent onset of pathergy,
abscesses, severe cystic acne, and pyoderma gangrenosum.
Typically, both articular and cutaneous outcomes occur
following a minor trauma. PSTPIP1 may interact with
NLRP3 and caspase-1 but a clear involvement of IL-1b is
still controversial. While anti-IL1 treatment seems to be
effective on joint manifestations, IL inhibition does not
display the same effectiveness in the management of skin
lesions.
Objectives
To investigate in our PAPA cohort whether 1) PSTPIP1
mutated monocytes display enhanced IL1b secretion; 2)
different PSTPIP1 mutations and/or clinical manifesta-
tions and disease activity correlate with degree in IL1b
pathway activation; 3) IL1b release is mediated by NLRP3.
Methods
Fourteen PAPA patients were examined. Thirteen
genetically confirmed patients (2 children and 11 adults)
carrying different PSTPIP1 mutations (N=11 E250Q,
N=1 E250K, N=1 E256G) and 1 pediatric patient geneti-
cally negative for common PSTPIPI1 variants, were ana-
lyzed and compared to 30 healthy donors (HD). Peripheral
blood primary human monocytes were freshly isolated and
studied at baseline and after 3-6-18 hours (h) of LPS-
induced in vitro activation, and pattern of IL-1b secretion
was assessed by ELISA. The involvement of NLRP3 was
investigated by in vitro silencing.
Results
Monocytes isolated from PAPA patients tend to secrete
higher levels of IL1b but variability occur even in the
presence of the same PSTPIP1 variant. IL1 b secretion
is higher in patients displaying prevalent articular vs
skin manifestations, and increases in the presence of
acute phase reactants elevation and/or joint/skin lesions.
The blockage of NLRP3 activity leads to IL1 release
inhibition in both PAPA and HD monocytes.
Conclusion
IL1 b secretion is higher in PAPA patients displaying
prevalent articular vs skin manifestations, correlates
with disease activity and is mediated by NLRP3.
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